profit from every $100 of sales.
$0$100
Arrowhead Pharmaceuticals
$49.36+0.73% today
+18.9% in 1 year
1-year low $38.091-year high $89.59
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Arrowhead Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $243 million in 2022 to $829 million in 2025, with -$1.63 million of profit last year.
SalesProfit
Arrowhead Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Arrowhead Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Arrowhead Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 88 | 138 | 243 | 241 | 4 | 829 | |
| – | – | – | – | – | – | |
| -93 | -149 | -179 | -205 | -601 | 98 | |
| -87 | -133 | -162 | -176 | -562 | 165 | |
| -85 | -141 | -176 | -205 | -599 | -2 | |
| -0.84 | -1.36 | -1.67 | -1.92 | -5.00 | -0.01 | |
| – | – | – | – | – | – | |
| -105.9% | -107.8% | -73.4% | -85.2% | -16,927.1% | 11.9% | |
| -96.1% | -101.9% | -72.4% | -85.3% | -16,882.4% | -0.2% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 523 | 710 | 692 | 766 | 1,140 | 1,385 |
| Cash | – | – | 108 | 111 | 76 | 89 |
| Total debt | – | – | 82 | 115 | 511 | 366 |
| Total liabilities | – | – | 274 | 478 | 949 | 882 |
| 462 | 409 | 399 | 271 | 185 | 466 | |
| 101 | 104 | 106 | 107 | 120 | 134 | |
| -15.9% | -27.2% | -28.4% | -38.5% | -65.8% | 13.4% | |
| -18.3% | -34.5% | -44.2% | -75.7% | -323.3% | -0.3% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -96 | 171 | -136 | -154 | -463 | 180 | |
| 12 | 24 | 53 | 177 | 141 | 23 | |
| -108 | 148 | -189 | -331 | -604 | 157 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 43 | 77 | 121 | 78 | 74 | 63 |
Valuation
- –
- –
- –
- 17.6×
- 8.4×
- 44.3×
- 43.9×
- 2.3%
- -0.0%
- 0.0%
Profitability
- 99.0%
- 11.9%
- -0.2%
- -26.0%
- 13.7%
- -30.6%
- -55.4%
- -13.3%
- -11.2%
- 109.6%
Growth
- +56.6%
- –
- +126.0%
- –
- +8.1%
Financial health
- 1.7×
- 0.79
- 60.5%
- 1.6×
- 4.86
- 6.23
- 0.27
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 16%of 958
Top 43%of 889
Top 10%of 890
Top 41%of 987
What analysts expect
- Average price target
- $81.22
- Range
- $35.00 – $110.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.93 | -1.18 | +21.2% |
| Feb 5, 2026 | 0.22 | 0.60 | −63.3% |
| Nov 25, 2025 | -0.18 | -0.11 | −61.3% |
| Aug 7, 2025 | -1.26 | -0.94 | −34.0% |
| May 12, 2025 | 2.75 | -0.06 | +4,683.3% |
| Feb 10, 2025 | -1.39 | -0.42 | −231.0% |
| Nov 26, 2024 | -1.38 | -1.05 | −31.4% |
| Aug 8, 2024 | -1.38 | -0.58 | −137.9% |
News
Arrowhead reports lower pancreatitis rates, early cholesterol drug resultsSeeking Alpha · Nov 8, 2026Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studiesSeeking Alpha · Aug 30, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
37No pass
Philip Fisher
48No pass
Peter Lynch
71Pass
Joel Greenblatt
10No pass
Charlie Munger
31No pass
Terry Smith
40No pass
Questions about Arrowhead Pharmaceuticals
Is Arrowhead Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Arrowhead Pharmaceuticals AI analysis
What does Arrowhead Pharmaceuticals do?
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. It is in Biotechnology, based in Pasadena, CA, United States, with 711 employees.
Does Arrowhead Pharmaceuticals pay a dividend?
No. Arrowhead Pharmaceuticals does not pay a dividend at the moment.
Is Arrowhead Pharmaceuticals stock halal?
Yes. Arrowhead Pharmaceuticals passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
How has Arrowhead Pharmaceuticals stock done over the past year?
Up 18.9% over the past twelve months, to $49.36. It traded between $38.09 and $89.59 and is 44.9% below its high.
Who are Arrowhead Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Arrowhead Pharmaceuticals's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.